CompletedNot Applicable

Evaluation of Anti-venoms Serum in Africa

Cameroon474 participantsStarted 2019-10-17

Plain-language summary

There is little or no assessment under real-use conditions of the efficacy and the tolerance in the short, medium and long term of the antivenoms currently on the market and used in the treatment of snake bites. The main objective is to assess the short term tolerance (\< 2 hours post-injection) of the antivenom Inoserp Pan-Africa® (temporary market authorization) from Inosan laboratory currently available in Cameroon.

Who can participate

Age range5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Any patient over 5 years old (inclusive) visiting at a participating center for a snake bite with or without confirmed envenoming * Informed consent to research Exclusion Criteria: * Patient refusal * Under 5 year-old * Antivenom serum administration before the arrival in the participating center * History of severe allergic reactions to antivenom serum

What they're measuring

Short term tolerance of the antivenom serum Inoserp Pan-Africa®

Timeframe: 30 months

Trial details

NCT IDNCT03326492

SponsorInstitut Pasteur

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2021-09-14

View on ClinicalTrials.gov More Snake Bites trials